Heart failure drugs market

April 2019 | 88 pages | ID: HA5DAD33348EN
Infoholic Research

Abstracts

Global Heart Failure Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025

[88 pages report] This market research report includes a detailed segmentation of the global heart failure drugs market by drug class (ACE inhibitors, beta blockers, diuretics, angiotensin receptor blockers, and others) and by region (North America, Europe, Asia Pacific, and Rest of the World).

Overview of the Global Heart Failure Drugs Market

Infoholic’s market research report predicts that the “Global Heart Failure Drugs Market” will grow at a CAGR of 9.1% during the forecast period. The market has witnessed good growth in the past few years and is sustaining due to increasing elderly population and increasing prevalence of cardiovascular diseases.

The growing market trend continues and is one of the progressively accepted markets in many countries worldwide. Heart failure drugs manufacturers are concentrating on procurement of funds and collaborating with universities to expand their R&D capabilities. Most of the revenue is generated from the leading players in the market with dominant sales from Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, Bayer AG, and Pfizer Inc.

According to Infoholic Research analysis, North America leads the global heart failure drugs market in 2018 followed by Europe. The US dominates the market owing to the presence of a majority of the heart failure drugs manufacturers in the region. However, the fastest growth rate is anticipated to be in the APAC region due to the presence of large heart failure patient population and availability of wide range of drugs.

By Drug Class:

• ACE Inhibitors
• Angiotensin Receptor Blockers
• Beta Blockers
• Diuretics
• Others

The diuretics segment occupied the largest share in 2018. The existing guiding principle by the American College of Cardiology and the American Heart Association recommends that diuretics should be directed at doses adequate to attain optimum volume station and release cramming without making an extremely fast drop in intravascular capacity.

By Regions:

• North America
• Europe
• APAC
• RoW

North America is dominant in the global heart failure drugs market followed by Europe. The Duke University in North Carolina, US in collaboration with National Heart, Lung, Blood Institute (NHLBI) and Yale University is conducting phase III clinical trial “TRANSFORM-HF” a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure.

Heart Failure Drugs Market Research Competitive Analysis – The market is growing at a steady rate with a CAGR of 9.1% during the forecast period 2019–2025. Merger and acquisition, product launches, and strategic collaborations are some of the major strategies adopted by market leaders to maintain their leadership position in the market. For example, in February 2019, Amgen, Cytokinetics, and Servier initiated the METEORIC-HF, the second phase III clinical trial of omecamtiv mecarbil in patients with heart failure.

Universities and educational institutions are collaborating with the market players to develop effective drugs for the treatment of the heart failure. For instance, Yale University in collaboration with Boehringer Ingelheim is currently conducting a phase II clinical study; a minor pilot proof of concept study to not only prove the existence but also probe the mechanisms that are fundamental for the cardio-renal effects of empagliflozin in patients with heart failure.

Key Vendors:

• Novartis AG
• GlaxoSmithKline PLC
• AstraZeneca PLC
• Bayer AG
• Pfizer, Inc.

Key Competitive Facts

• Sclnow Biotechnology Co., Ltd. is studying to access the safety and efficiency of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating individuals suffering from heart failure. This treatment is in phase 1/2 currently.
• In January 2019, Sanofi and MyoKardia ended their heart disease drug collaboration.

Benefits – The report provides complete details about the sub-segments of the heart failure drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

Key Takeaways:

• Understanding the potential market opportunity with precise market size and forecast data.
• A detailed market analysis focusing on the growth of heart failure drugs industry.
• Factors influencing the growth of the heart failure drugs market.
• In-depth competitive analysis of dominant and pureplay vendors.
• Prediction analysis of the heart failure drugs market in both developed and developing regions.
• Key insights related to major segments of the heart failure drugs market.
• Latest market trend analysis impacting the buying behavior of the consumers.

Key Stakeholders

Contents

1 INDUSTRY OUTLOOK

1.1 Industry Overview
1.2 Total Addressable Market
  1.2.1 Industry Trends

2 REPORT OUTLINE

2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 MARKET SNAPSHOT

3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Industry Trends
3.4 Related Markets
  3.4.1 Drug Eluting Stents
  3.4.2 Active Pharmaceutical Ingredients (APIs)
  3.4.3 Over the Counter Drugs (OTC)

4 MARKET OUTLOOK

4.1 Market Segmentation
4.2 Porter 5 (Five) Forces

5 MARKET CHARACTERISTICS

5.1 Guidelines Summary
5.2 Market Dynamics
  5.2.1 Drivers
    5.2.1.1 Increasing elderly population
    5.2.1.2 Increasing incidence of cardiovascular device across the globe
  5.2.2 Restraints
    5.2.2.1 Complex drug development process
    5.2.2.2 Adverse effects of heart failure drugs
  5.2.3 Opportunities
    5.2.3.1 Market expansion opportunities in emerging nations
    5.2.3.2 Novel heart failure medicines to fill the gap of unmet need in treatment
  5.2.4 DRO – Impact Analysis
5.3 Key Stakeholders

6 TECHNOLOGY TYPES: MARKET SIZE AND ANALYSIS

6.1 Overview
6.2 Beta Blockers
6.3 ACE Inhibitors
6.4 Angiotensin Receptor Blockers (ARBs)
6.5 Diuretic
6.6 Others

7 REGIONS: MARKET SIZE AND ANALYSIS

7.1 Overview
7.2 North America
  7.2.1 Overview
  7.2.2 US
  7.2.3 Canada
7.3 Europe
  7.3.1 Overview
  7.3.2 UK
  7.3.3 Germany
7.4 Asia Pacific
  7.4.1 Overview
  7.4.2 India
  7.4.3 China
  7.4.4 Japan
7.5 Rest of the World
  7.5.1 Overview
  7.5.2 Africa
  7.5.3 Brazil

8 COMPETITIVE LANDSCAPE

9 VENDORS PROFILE

9.1 Novartis AG
  9.1.1 Overview
  9.1.2 Business Units
  9.1.3 Geographic Presence
  9.1.4 Business Focus
  9.1.5 SWOT Analysis
  9.1.6 Business Strategy
9.2 GlaxoSmithKline plc
  9.2.1 Overview
  9.2.2 Business Units
  9.2.3 Geographic Presence
  9.2.4 Business Focus
  9.2.5 SWOT Analysis
  9.2.6 Business Strategy
9.3 Bayer AG
  9.3.1 Overview
  9.3.2 Business Unit
  9.3.3 Geographic Presence
  9.3.4 Business Focus
  9.3.5 SWOT Analysis
  9.3.6 Business Strategy
9.4 Astra Zeneca PLC
  9.4.1 Overview
  9.4.2 Business Units
  9.4.3 Geographic Presence
  9.4.4 Business Focus
  9.4.5 SWOT Analysis
  9.4.6 Business Strategies
9.5 Pfizer, Inc.,
  9.5.1 Overview
  9.5.2 Business Units
  9.5.3 Geographic Presence
  9.5.4 Business Focus
  9.5.5 SWOT Analysis
  9.5.6 Business Strategies

10 COMPANIES TO WATCH FOR

10.1 Merck & Co
  10.1.1 Overview
10.2 Boehringer Ingelheim GmbH
  10.2.1 Overview
10.3 Bristol-Myers Squibb
  10.3.1 Overview
10.4 Mylan N.V.
  10.4.1 Overview
10.5 Sanofi
  10.5.1 Overview
10.6 Amgen Inc.
  10.6.1 Overview
Annexure
Acronyms

List Of Tables

LIST OF TABLES

TABLE 1 TOP ACQUISITIONS IN CARDIOVASCULAR INDUSTRY
TABLE 2 HEART FAILURE DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2018–2025 ($MILLION)
TABLE 3 PROJECTIONS – CVD TOTAL COSTS THROUGH 2035
TABLE 4 PRESCRIPTIONS USED IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE IN UK
TABLE 5 NUMBER OF PEOPLE WITH THE FOUR HEART CONDITIONS IN BRAZIL, 2015
TABLE 6 NOVARTIS AG: OFFERINGS
TABLE 7 NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 8 GLAXOSMITHKLINE PLC: OFFERINGS
TABLE 9 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 10 BAYER AG: OFFERINGS
TABLE 11 BAYER AG: RECENT DEVELOPMENTS
TABLE 12 ASTRAZENECA PLC: OFFERINGS
TABLE 13 ASTRAZENECA PLC: RECENT DEVELOPMENTS
TABLE 14 PFIZER, INC.: OFFERINGS
TABLE 15 PFIZER, INC.: RECENT DEVELOPMENTS
TABLE 16 MERCK & CO: SNAPSHOT
TABLE 17 MERCK & CO: RECENT DEVELOPMENTS
TABLE 18 BOEHRINGER INGELHEIM GMBH: SNAPSHOT
TABLE 19 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS
TABLE 20 BRISTOL-MYERS SQUIBB: OVERVIEW
TABLE 21 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENTS
TABLE 22 MYLAN N.V.: OVERVIEW
TABLE 23 MYLAN N.V.: RECENT DEVELOPMENTS
TABLE 24 SANOFI: SNAPSHOT
TABLE 25 SANOFI: RECENT DEVELOPMENTS
TABLE 26 AMGEN INC.: OVERVIEW
TABLE 27 AMGEN INC.: RECENT DEVELOPMENTS

CHARTS

CHART 1 GLOBAL CARDIOVASCULAR DISEASE MARKET 2017 ($BILLION)
CHART 2 RESEARCH METHODOLOGY OF GLOBAL HEART FAILURE DRUGS MARKET
CHART 3 HEART FAILURE DRUGS MARKET REVENUE, 2018–2025 ($MILLION)
CHART 4 HEART FAILURE DRUGS MARKET SEGMENTATION
CHART 5 PORTERS 5 FORCES ON HEART FAILURE DRUGS MARKET
CHART 7 MARKET DYNAMICS – DRIVERS, RESTRAINTS & OPPORTUNITIES
CHART 8 DRO - IMPACT ANALYSIS OF HEART FAILURE DRUGS MARKET
CHART 9 KEY STAKEHOLDERS OF HEART FAILURE DRUGS MARKET
CHART 10 HEART FAILURE DRUGS MARKET SEGMENT REVENUE BY TECHNOLOGY TYPE, 2018 VS 2025 ($ MILLION)
CHART 11 BETA BLOCKERS MARKET REVENUE, BY TECHNOLOGY TYPE 2018–2025 ($MILLION)
CHART 12 ACE INHIBITOR EDITING MARKET REVENUE, BY TECHNOLOGY TYPE 2018–2025 ($MILLION)
CHART 13 ANGIOTENSIN RECEPTOR BLOCKERS (ARBS) MARKET REVENUE, BY TECHNOLOGY TYPE 2018–2025 ($MILLION)
CHART 14 DIURETIC HEART FAILURE DRUGS MARKET REVENUE, BY TECHNOLOGY TYPE 2018–2025 ($MILLION)
CHART 15 OTHER HEART FAILURE DRUGS MARKET REVENUE, BY TECHNOLOGY TYPE 2018–2025 ($MILLION)
CHART 16 HEART FAILURE DRUGS MARKET BY REGIONAL SEGMENTATION, 2018 ($MILLION)
CHART 17 HEART FAILURE DRUGS MARKET BY REGIONAL SEGMENTATION, 2025 ($MILLION)
CHART 18 HEART FAILURE DRUGS MARKET REVENUE IN NORTH AMERICA, 2018–2025 ($MILLION)
CHART 19 HEART FAILURE DRUGS MARKET REVENUE IN EUROPE, 2018–2025 ($MILLION)
CHART 20 HEART FAILURE DRUGS MARKET REVENUE IN ASIA PACIFIC, 2018–2025 ($MILLION)
CHART 21 HEART FAILURE DRUGS REVENUE IN REST OF THE WORLD, 2018–2025 ($MILLION)
CHART 22 NOVARTIS AG: OVERVIEW SNAPSHOT
CHART 23 NOVARTIS AG: BUSINESS UNITS
CHART 24 NOVARTIS AG: GEOGRAPHICAL PRESENCE
CHART 25 NOVARTIS AG: SWOT ANALYSIS
CHART 26 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT
CHART 27 GLAXOSMITHKLINE PLC: BUSINESS UNITS
CHART 28 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE
CHART 29 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
CHART 30 BAYER AG: OVERVIEW SNAPSHOT
CHART 31 BAYER AG: BUSINESS UNITS
CHART 32 BAYER AG: GEOGRAPHICAL PRESENCE
CHART 33 BAYER AG: SWOT ANALYSIS
CHART 34 ASTRAZENECA PLC: OVERVIEW SNAPSHOT
CHART 35 ASTRAZENECA PLC: BUSINESS UNITS
CHART 36 ASTRAZENECA PLC: GEOGRAPHIC PRESENCE
CHART 37 ASTRAZENECA PLC: SWOT ANALYSIS
CHART 38 PFIZER, INC.: OVERVIEW SNAPSHOT
CHART 39 PFIZER, INC.: BUSINESS UNITS
CHART 40 PFIZER, INC.: GEOGRAPHIC PRESENCE
CHART 41 PFIZER, INC: SWOT ANALYSIS